Analysts Set Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Target Price at $36.60

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) has been given an average recommendation of "Buy" by the five analysts that are currently covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $36.60.

KNSA has been the subject of a number of research reports. Wedbush reaffirmed an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Monday, January 13th. Evercore ISI boosted their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th.

Kiniksa Pharmaceuticals Price Performance

Shares of NASDAQ:KNSA traded up $0.37 on Monday, reaching $19.65. The company's stock had a trading volume of 268,807 shares, compared to its average volume of 578,559. The stock's 50-day moving average is $19.86 and its two-hundred day moving average is $22.94. Kiniksa Pharmaceuticals has a 52-week low of $16.56 and a 52-week high of $28.15. The stock has a market capitalization of $1.42 billion, a P/E ratio of -140.35 and a beta of 0.32.

Insider Transactions at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 8,969 shares of the company's stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total transaction of $192,385.05. Following the transaction, the chief financial officer now directly owns 22,958 shares in the company, valued at approximately $492,449.10. This represents a 28.09 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Eben Tessari sold 14,000 shares of the company's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the transaction, the chief operating officer now owns 81,975 shares in the company, valued at $1,604,250.75. The trade was a 14.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,092 shares of company stock worth $745,589 over the last ninety days. 54.57% of the stock is currently owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals

Large investors have recently modified their holdings of the business. Wellington Management Group LLP acquired a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $1,192,000. JPMorgan Chase & Co. acquired a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at approximately $4,997,000. Parkman Healthcare Partners LLC lifted its stake in shares of Kiniksa Pharmaceuticals by 16.7% during the third quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company's stock valued at $18,874,000 after buying an additional 108,102 shares during the period. Segall Bryant & Hamill LLC purchased a new position in shares of Kiniksa Pharmaceuticals during the third quarter valued at approximately $675,000. Finally, SG Americas Securities LLC purchased a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter valued at approximately $355,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.